Researchers in Belgium have suggested that giving birth slows the progression of multiple sclerosis (MS). The results of their study are published in the Journal of Neurology Neurosurgery and Psychiatry.

View post:
Childbirth May Slow MS – Multiple Sclerosis Society

Related posts:

1. Husband’s Studies Lead To Clinical Trial – Multiple Sclerosis SocietyNews reports this week have detailed the research of Canadian scientists Dr Paolo Zamboni, who is a professor of medicine at the University of Ferrara in Italy and whose wife...
2. Multiple Sclerosis: What Part Do Relapses Play In Severe Disability?People with multiple sclerosis (MS) who have relapses within the first five years of onset appear to have more severe disability in the short term compared to people who do...
3. Study Confirms That Cannabis Is Beneficial For Multiple SclerosisCannabis can reduce spasticity in multiple sclerosis (MS) patients. A systematic review, published in the open access journal BMC Neurology, found that five out six randomized controlled trials reported a...
4. Real-Time Observation Sheds New Light On Multiple SclerosisIn diseases such as multiple sclerosis, cells of the immune system infiltrate the brain tissue, where they cause immense damage. For many years, it was an enigma as to how...
5. Mayo Clinic Neurologist Reports: "Thousands Of NMO Patients Are Misdiagnosed With Multiple Sclerosis"Thousands of Neuromyelitis Optica (NMO) patients are potentially being misdiagnosed with Multiple Sclerosis (MS), according to Mayo Clinic Neurologist Sean Pittock, M.D., largely due to lack of awareness of NMO...
6. Three Important Points – Multiple Sclerosis TreatmentWhen it comes to neurological diseases which are debilitating, Multiple Sclerosis is the one most commonly found amongst the young. It is usually strikes between the ages of 20 and...
7. MS Society Of Canada Announces Request For Research Operating Grants Related To CCSVI And MSThe Multiple Sclerosis Society of Canada announced it will request research operating grants related to chronic cerebrospinal venous insufficiency (CCSVI) and MS. A recent study released by Dr. ...
8. Stomach Hormone Can Boost Resistance To Or Slow Down Parkinson’s, StudyUS researchers report finding that ghrelin, a hormone produced in the stomach that regulates appetite and how the body deposits fat, may be used to boost resistance to or slow...
9. Teenage Obesity Linked To Increased Risk Of MSTeenage women who are obese may be more than twice as likely to develop multiple sclerosis (MS) as adults compared to female teens who are not obese, according to a...
10. Drug Shows Positive Responses, Low Side-Effects In Multiple MyelomaThe second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a phase II clinical trial, researchers reported at...
11. New Study Ushers In Spring-Time For Slow InactivationThe December 2009 issue of the Journal of General Physiology (JGP) contains a paper by Christopher Ahern (The University of British Columbia, Vancouver) and colleagues that explores pore mutation effects...
12. American Chemical Society, Royal Society Of Chemistry Agree To Joint Global Sustainability EffortsTwo of the world's largest chemical societies have pledged to work cooperatively to contribute to global efforts aimed at developing sustainable energy, providing abundant food and clean water, and seeking...
13. Carfilzomib Demonstrates Encouraging Response Rates In Patients With Relapsed And/or Refractory Multiple Myeloma In An Ongoing Phase 2 StudyOnyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced results from an ongoing Phase 2 study, known as the 004 study, of the company's lead proteasome inhibitor, carfilzomib. Results demonstrated promising overall response...
14. Fast Bandaid Removal Less Painful Than Slow Bandaid RemovalA randomised trial has found that fast bandaid removal is less painful to healthy young adults than slow bandaid removal, according to a report published in the Medical Journal of...
15. Facet Biotech And Bristol-Myers Squibb Report Promising Phase I/II Interim Data For Elotuzumab In Patients With Relapsed Multiple MyelomaFacet Biotech Corporation (NASDAQ: FACT) and Bristol-Myers Squibb Company (NYSE: BMY) announced that potentially promising data from a Phase I/II study of elotuzumab, an investigational humanized antibody being studied for...